(M12) M1 Kliniken - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE000A0STSQ8
M12: Aesthetic Surgery, Plastic Surgery, Pharmaceuticals, Medical Products
M1 Kliniken AG, together with its subsidiaries, provides aesthetic medicine and plastic surgery services in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. It operates in two segments, Beauty and Trade. The Beauty segment provides aesthetic surgery services, such as breast augmentation, eyelid lifts, and liposuction; and other aesthetic medical treatment services, including injections with hyaluronic acid and botulinum toxin. This segment also manages a private clinic for plastic and aesthetic surgery; and medical specialist centers for aesthetic and plastic medicine under the Schlossklinik and M1 Med Beauty names. The Trade segment sells pharmaceuticals and medical products for various therapeutic areas comprising oncology, HIV/AIDS, neurology, rheumatology, other chronic diseases, and aesthetic medicine. The company was incorporated in 2007 and is based in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG. Web URL: https://www.m1-kliniken.de
Additional Sources for M12 Stock
M12 Stock Overview
| Market Cap in USD | 327m |
| Sector | Healthcare |
| Industry | Medical Distribution |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
M12 Stock Ratings
| Growth 5y | 10.4% |
| Fundamental | 73.6% |
| Dividend | 28.0% |
| Rel. Strength Industry | 1421 |
| Analysts | - |
| Fair Price Momentum | 14.75 EUR |
| Fair Price DCF | 30.29 EUR |
M12 Dividends
| Dividend Yield 12m | 3.28% |
| Yield on Cost 5y | 3.12% |
| Annual Growth 5y | % |
| Payout Consistency | 48.5% |
M12 Growth Ratios
| Growth Correlation 3m | -75.7% |
| Growth Correlation 12m | 49.6% |
| Growth Correlation 5y | 18.4% |
| CAGR 5y | -0.98% |
| CAGR/Mean DD 5y | -0.02 |
| Sharpe Ratio 12m | 0.91 |
| Alpha | 30.84 |
| Beta | 0.56 |
| Volatility | 42.44% |
| Current Volume | 6.5k |
| Average Volume 20d | 10.8k |
What is the price of M12 stocks?
As of January 22, 2025, the stock is trading at EUR 15.25 with a total of 6,469 shares traded.
Over the past week, the price has changed by -1.61%, over one month by -6.15%, over three months by -8.68% and over the past year by +50.96%.
As of January 22, 2025, the stock is trading at EUR 15.25 with a total of 6,469 shares traded.
Over the past week, the price has changed by -1.61%, over one month by -6.15%, over three months by -8.68% and over the past year by +50.96%.
Is M1 Kliniken a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, M1 Kliniken (XETRA:M12) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 73.56 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of M12 as of January 2025 is 14.75. This means that M12 is currently overvalued and has a potential downside of -3.28%.
Yes, based on ValueRay Fundamental Analyses, M1 Kliniken (XETRA:M12) is currently (January 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 73.56 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of M12 as of January 2025 is 14.75. This means that M12 is currently overvalued and has a potential downside of -3.28%.
Is M12 a buy, sell or hold?
M1 Kliniken has no consensus analysts rating.
M1 Kliniken has no consensus analysts rating.
What are the forecast for M12 stock price target?
According to ValueRays Forecast Model, M12 M1 Kliniken will be worth about 16.1 in January 2026. The stock is currently trading at 15.25. This means that the stock has a potential upside of +5.57%.
According to ValueRays Forecast Model, M12 M1 Kliniken will be worth about 16.1 in January 2026. The stock is currently trading at 15.25. This means that the stock has a potential upside of +5.57%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 28 | 83.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.1 | 5.6% |